𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of infections in hickman and implanted port catheters in adult solid tumor patients

✍ Scribed by David Pegues; Peter Axelrod; Carol McClarren; Burton L. Eisenberg; John P. Hoffman; Faith D. Ottery; Richard D. Keidan; Marcia Boraas; James Weese


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
629 KB
Volume
49
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Long-term therapy of oncology patients has been facilitated by permanent indwelling central venous catheters, but catheter-related infections remain a serious complication of their use. Using a retrospective matched cohort design, we compared the risk of catheter-related infection in 47 adult solid tumor patients with right atrial Hickman catheters and 94 patients with totally implanted port catheters. Patients were matched for primary solid tumor, presence of metastases, age, gender, and date of catheter insertion. Seven of 47 patients with Hickman catheters developed catheter-related infection (1.8 infectiondl ,000 catheter days at risk) compared with 10 of 94 patients with implanted port catheters (0.4/1000 catheter days, P < 0.0002). Hickman catheters were used more often for terminally ill patients than were port catheters which was a potential source of bias, but results were unchanged after stratifying patients on lifespan. Our study suggests that there are fewer infections in port than in Hickman catheters in adult patients with solid tumors, but prospective randomized studies are needed.


πŸ“œ SIMILAR VOLUMES


High-dose chemotherapy and immunotherapy
✍ Albert Oriol; Josep-Maria Ribera; Juan Bergua; Eduardo GimΓ©nez Mesa; Carlos Gran πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 160 KB

## Abstract ## BACKGROUND. It has been recognized that cure is possible for human immunodeficiency virus (HIV)‐infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used. The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome

Comparison of tumor response by Response
✍ Julien Edeline; Eveline Boucher; Yan Rolland; Elodie VaulΓ©on; Marc Pracht; Chris πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 578 KB

## Abstract ## BACKGROUND: A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed